key: cord-0760336-qv44weub
authors: Phipps, Meaghan M.; Verna, Elizabeth C.
title: COVID‐19 and liver transplantation: Lessons from the first year of the pandemic
date: 2021-06-05
journal: Liver Transpl
DOI: 10.1002/lt.26194
sha: 45b946971d84bb90311186a111415e667fe21db2
doc_id: 760336
cord_uid: qv44weub

Over the last year, novel coronavirus‐19 (COVID‐19) has continued to spread across the globe, causing significant morbidity and mortality among transplant candidates and recipients. Patients with end stage liver disease awaiting liver transplantation and patients with a history of liver transplantation represent vulnerable populations, especially given high rates of associated medical comorbidities in these groups and their immunosuppressed status. In addition, concerns surrounding COVID‐19 risk in this patient population has affected rates of transplantation and general transplantation practices. Here, we explore what we have learned about the impact of COVID‐19 on liver transplant candidates and recipients as well as the many key knowledge gaps that remain.

for liver transplantation than expected, with 34% fewer deceased donor liver transplants. Over this period, transplant centers in these states had 59% more waitlist deaths than expected. 10 Interestingly, even within geographic areas with similar COVID-19 rates, there were significant variations in transplantation practices between individual centers. When changes in adult deceased donor liver transplantation (DDLT) in the month preceding and following the onset of widespread COVID-19 infection in the US were evaluated, there was an 11% decrease in deceased donors from February to March 2020 overall, with a resultant decrease in adult DDLTs nationally of 24.7%. When region and center were considered, there was much greater variability seen in 2020 compared with 2019 when looking at transplantation practices within the same region, despite similar rates of COVID-19 at these centers. This was observed among regions with high and low rates of COVID-19, although notably with some of the highest within-region variability seen in that with the highest burden of COVID-19 cases (such as Region 9). 11 It is not clear what accounts for these differences, though it is possible that center-specific resources, COVID-19 transmission among transplant team members, and center leadership philosophy regarding risk may have played a role.

Despite the risks and unknowns, these early effects of the pandemic and associated uncertainly upon wait listing and transplant rates are largely seen for the first 2 months of the pandemic, with subsequent numbers near pre-pandemic levels. Interestingly in the months that followed and the burden of COVID-19 cases shifted between states, waitlist registrations, rates of transplantation, and waitlist mortality were very near expected in new high incidence areas. 10 While data regarding the impact of COVID-19 upon liver transplant rates and practices must be interpreted in the context of the virtually simultaneous change in the liver allocation system in February 2020 12 , the restoration of transplant volume may also be attributed to the increase in the available of testing for donors and recipients, as well as the rapid move to create guidance surrounding COVID-19 from UNOS as well as our core societies. 13, 14 

This article is protected by copyright. All rights reserved Patients with chronic liver disease (CLD) and cirrhosis have been greatly affected by COVID-19 ( Table   1 ). Since the early reports of the clinical characteristics of COVID- 19 , it has been clear that liver injury as measured by both elevations in liver enzymes as well as post-mortem pathology has been common, perhaps a particular threat to patients with decompensated liver disease. [15] [16] [17] [18] [19] Liver enzyme elevations have been reported in up to 63% of patients with COVID-19 infection, with a more severe disease course including higher rates of intensive care unit (ICU) admission, intubation, renal replacement therapy (RRT), and mortality seen in patients with marked elevations 2,20,21 . In addition, there have been reports of less common but more severe forms of liver disease in the context of COVID-19 that could create additional indications for liver transplantation, including acute liver failure 22 as well as progressive cholangiopathy 23 .

While patients with CLD do not appear to be overrepresented in the largest epidemiological cohorts 24 , it does appear that patients with CLD overall are at increased risk of severe disease and death. 6, 7 This has been demonstrated in large dataset analyses, including a study of 2780 patients with SARS-CoV-2 infection across 34 centers in the US, of whom 250 (9%) were identified as having CLD, including 50 (1.8%) with cirrhosis. In propensity-score-matched analysis (matched for body mass index, hypertension, diabetes, age, race, and nicotine use), CLD was associated with a significantly higher risk of mortality in patients than those without liver disease, and this risk was greatest among patients with cirrhosis. Rates of hospitalization were also higher in patients with CLD compared with those without liver disease. 6 Similarly, in a study of over 17 million patients in the United Kingdom, CLD was associated with an increased risk of COVID-19-related death. 24 However, it is likely that both the etiology of CLD as well as the disease severity impact this risk, and it is possible that cirrhosis is underdiagnosed in these large datasets. [25] [26] [27] There were also several early multicenter reports of outcomes among patients with cirrhosis throughout the world. Among 50 patients with cirrhosis and confirmed SARS-CoV-2 infection at 9 centers in Italy, the 30-day mortality rate was 34%, which was significantly higher than that of patients hospitalized over the previous year for hepatic decompensation in the setting of bacterial

This article is protected by copyright. All rights reserved infection. 28 In addition, in a cohort that included 43 patients with cirrhosis from 13 Asian countries with COVID-19, 20% presented with acute-on-chronic liver failure or decompensation from baseline. 29 Finally, in a report of 21 patients with cirrhosis from 16 hospitals in China, 23.8% died.

There were no significant predictors of mortality, with liver-specific risk factors such as etiology of cirrhosis, Child-Turcotte-Pugh (CTP) class, and Model for End Stage Liver Disease (MELD) score similar between patients who survived and those who did not, though this cohort is likely too small to draw firm conclusions. 30 Following these initial reports, several larger studies from the US and multinational cohorts have further refined our understanding of the relationship between chronic liver disease and cirrhosis and COVID-19 outcomes. In the COLD consortium, 867 patients across 21 US centers were identified with CLD (71.5% with cirrhosis, 10.7% with decompensated cirrhosis) and confirmed SARS-CoV-2 infection. The presence of gastrointestinal manifestations including diarrhea or nausea/vomiting, Hispanic ethnicity, and decompensated cirrhosis were associated with increased risk of severe COVID-19. Alcohol-related liver disease was associated with higher mortality (HR 2.42, 1.29-4.55), as was decompensated cirrhosis (HR 2.91, 1.70-5.00) and hepatocellular carcinoma (HR 3.31, 1.53-7.16). Medical comorbidities including older age, diabetes, hypertension, chronic obstructive pulmonary disease, and current smoking were also associated with higher mortality. 25 Similarly, among 745 patients with CLD from 29 countries in the Secure Cirrhosis and COVID-Hep registries, patients with cirrhosis (n=386) had a mortality rate of 32% compared with only 8% in patients with CLD but no cirrhosis. In addition, among patients with cirrhosis, there was a stepwise increase in mortality with increasing CTP class. 46% of patients with cirrhosis had an acute decompensation from baseline, of whom 50% met criteria for acute-on-chronic liver failure. Multivariable analysis showed older age, cirrhosis (with any CTP class), and alcohol-related liver disease to be associated with increased risk for mortality. Propensity-score-matched analysis was performed using 620 patients without liver disease, which revealed significantly increased mortality in CTP class B and C cirrhosis. 26 There were similar findings in an international study comparing outcomes of 110 patients with autoimmune hepatitis (AIH) and COVID-19 with a propensity score-matched cohort of patients

This article is protected by copyright. All rights reserved with other etiologies of chronic liver disease and COVID-19. Severe course of COVID-19 and mortality rates were similar between groups. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH, but rates of severe COVID-19 and mortality were similar between groups. 31 However, it is also clear that this literature must be interpreted in the context of carefully selected control groups in order to understand what is driving these outcomes. When 37 patients with cirrhosis and COVID-19 were compared with two age and gender-matched comparator groups in a US-based multicenter study, patients with cirrhosis and COVID-19 had higher mortality than those without cirrhosis with COVID-19, but similar mortality rates when compared to patients with cirrhosis without COVID-19, perhaps indicating that cirrhosis itself is driving the high inpatient mortality rates. 32

There are no clinical trial data for the treatment of COVID-19 reported to date specifically among patients with cirrhosis and decompensated cirrhosis. There are significant concerns about the hepatotoxicity of several potential SARS-CoV-2 therapies including remdesivir, IL-6 inhibitors such as tocilizumab, and steroids. Remdesivir has been associated with elevation in AST and/or ALT in 10-50% of patients treated for SARS-CoV-2 in the trials to date [33] [34] [35] [36] [37] [38] , and is not currently recommended to be given for patients with baseline liver enzymes >5 times the upper limit of normal 39 . In addition, there are numerous studies regarding tocilizumab-related hepatotoxicity in the rheumatology literature, including reports of up to 71% of patients with liver injury in this context [40] [41] [42] . In the trials currently published of tocilizumab for the treatment of COVID-19, liver enzyme elevations were reported in over 15 % of patients, although these reflect only significant enzyme elevations. [43] [44] [45] In one recent study, for example, liver enzyme elevations were seen in over 80% of patients who received tocilizumab during their hospitalization; 46 the direct contribution of tocilizumab to abnormal liver tests in the majority of patients with COVID-19, especially among hospitalizated patients, is unknown given other competing etiologies of acute liver injury in this population, and most trials reported only marked enzyme elevations. Given the significant mortality associated with

This article is protected by copyright. All rights reserved severe COVID-19, the increased risk of severe disease in the context of liver enzyme elevation and the limited therapeutic options available, it will be important to report outcomes among patients with advanced liver disease who receive these agents.

Screening of donors (both deceased and living) and recipients at the time of transplant is now widely performed, although not yet standardized outside of society consensus statements. 13, 14, 47 All patients who present for transplantation should be tested for SARS-CoV2 with a nasopharyngeal PCR test prior to undergoing the operation. Current recommendations advise against transplantation in recipients with active COVID-19, and recommend proceeding to transplantation ideally 2-3 weeks after symptoms have resolved and at least one nasopharyngeal PCR test is negative, with some physicians recommending two negative tests. In addition, all donors should undergo a nasopharyngeal PCR test prior to acceptance of the organ offer. This has been variably implemented by organ procurement organizations and a more standardized approach might be helpful for the community. For potential living donors with prior SARS-CoV-2 infection , there should be at least one negative SARS-CoV-2 RNA test or if repeat testing remains positive, however only if the patient is asymptomatic and the infection was between 21 and 90 days prior to donor evaluation. 13, 14, 48 One unique challenge in this setting is the prolonged viral shedding that has been observed in patients with end stage liver disease, in particular those with NAFLD and non-alcoholic steatohepatitis, where PCR testing can remain positive beyond the time period expected in the general population. 49, 50 In addition, for patients who cannot wait, including those with acute liver failure or high MELD scores, it has been debated whether it is safe to proceed without negative testing, especially in the absence of respiratory symptoms. However, it is unknown whether extrapulmonary manifestations and/or immune activation in this setting will lead to significant complications in the post-transplant period. Further studies are needed in this patient population to better understand the risks and benefits of proceeding to transplantation and establish clear guidelines and recommendations.

This article is protected by copyright. All rights reserved Safety concerns related to SARS-CoV-2 infection in donors and recipients include both ongoing manifestations of COVID-19, which is increasingly recognized to have a prolonged effect, as well as concerns about immunologic events including rejection in the early post-operative period. Early in the pandemic, there were only a handful of case reports describing patients who successfully underwent DDLT after recovery from SARS-CoV-2 infection. [51] [52] [53] In these reports, all patients had recovered with negative polymerase chain reaction (PCR) tests prior to transplantation, with the earliest transplant occurring 36 days after onset of symptoms. In one case where the patient's induction immunosuppression regimen consisted of only steroids and a calcineurin inhibitor, the patient experienced acute rejection requiring thymoglobulin and high dose steroids, without any adverse events thereafter. There have since been larger case series describing both living donors and recipients with positive SARS-CoV-2 RT-PCR as recently as two weeks pre-transplant, without COVID-19-related complications. 54, 55 Although not well described to date, there has additionally been one case report of a patient with neutralizing antibodies to SARS-CoV-2 who received an organ from a patient who tested positive for SARS-CoV-2 at the time of procurement, with good graft function at 2 months follow-up. 56

Numerous studies have reported patient outcomes in liver transplant recipients with SARS-CoV-2 infection. Major findings from these studies are summarized in Table 2 .

In a study out of two centers in New York City during the first three weeks of the outbreak in this epicenter, ninety patients with a history of solid organ transplantation and COVID-19 infection were studied, of whom 13 patients had undergone liver transplantation and one simultaneous liverkidney transplantation. In this cohort, over 75% of patients had moderate or severe disease, with a mortality of 18% overall, without a difference in patient outcomes depending on type of organ transplant. 57

This article is protected by copyright. All rights reserved Early reports from European cohorts report similar findings, with a mortality rate of 16% in liver transplant recipients with SARS-CoV-2 infection from a database of 103 liver transplant recipients. In this cohort, mortality was only observed in patients 60 years of age or older, with no patient deaths reported among the 27 patients under the age of 60. 58 An additional Spanish cohort of 111 liver transplant recipients reported a similar mortality rate of 18%, interestingly lower than that of the matched general population. Multivariable analysis identified the Charlson comorbidity index, male gender, the presence of dyspnea at diagnosis, and baseline immunosuppression at diagnosis as risk factors for severe COVID-19. Again, in this cohort, there were no patient deaths reported in liver transplant recipients under the age of 60. 59, 60 As rates of COVID-19 have continued to climb, there have been additional studies from multicenter consortiums and large databases. In a multicenter cohort study from two international registries, 151 patients with SARS-CoV-2 infection and history of liver transplantation were evaluated and compared with 627 patients with SARS-CoV-2 infection without history of liver transplantation.

Increased age, serum creatinine, and non-liver cancer were associated with increased mortality rate.

In propensity score-matched analysis adjusting for age, sex, creatinine, obesity, hypertension, diabetes, and ethnicity, liver transplantation itself was not associated with death (absolute risk difference of 1.4%). 61 The COVID-19 in chronic liver disease (COLD) consortium also performed a multicenter observational cohort study, which included 112 liver transplant recipients from 15 medical centers in the US. The mortality rate among this cohort was 22.3%, with 72.3% of patients requiring hospitalization and 26.8% ICU-level care. 62 In a recent study using a large, multicenter research network, outcomes were compared between 43,508 non-liver transplant patients with COVID-19 and 126 liver transplant patients with COVID-19.

Propensity score matching (based on age, race, and key comorbidities) was performed, with higher risk of hospitalization observed in the liver transplant group compared with the non-liver transplant group (40% vs. 23%, respectively). In adjusted analysis, there was no difference observed in risk of mortality, thrombosis events, and ICU level care. 63 Thus, despite initial concern that the virus would

This article is protected by copyright. All rights reserved be much more severe among our immunosuppressed transplant recipients, it appears that when matched for other risk factors, transplant status is not predictive of outcomes. There have been similar finding in the solid organ transplant literature in general, raising important questions about the role of a hyperimmune response in the pathogenesis of severe COVID-19 and whether there are specific types of degrees of immunosuppression that may be helpful.

Treatment of COVID-19 in liver transplant recipients remains an area with limited data thus far. In some of the studies discussed earlier where COVID-19-targeted therapy was investigated, medications including remdesivir and anti-IL6-receptor monoclonal antibodies were given to liver transplant recipients without clear adverse events. 57, 61, [64] [65] [66] Larger patient cohorts are needed to further study the safety and efficacy of these therapies in this patient population.

An important consideration in the management of liver transplant recipients with COVID-19 is the approach to abnormalities in liver tests and the presence of acute liver injury. In a multicenter observational cohort in the US including 112 adult liver transplant recipients, the incidence of acute liver injury was lower in liver transplant recipients when compared with age and gender matched controls with chronic liver disease and COVID-19. However, among liver transplant recipients, rates of ICU admission and mortality were higher in patients with acute liver injury. 62 Acute liver injury and abnormalities in liver tests present a unique challenge in liver transplant recipients, where COVID-19 and rejection can co-exist. Reports of concomitant acute cellular rejection and acute hepatitis secondary to COVID-19 have been described in a liver allograft recipient 67 , highlighting the importance of liver biopsy in these patients given the laboratory abnormalities for rejection and COVID-19 may be indistinguishable from one another.

recipients is the approach to immunosuppression. One of the first studies to detail immunosuppression in liver transplant recipients with SARS-CoV-2 infection included a Spanish

This article is protected by copyright. All rights reserved cohort of 111 liver transplant recipients. In this cohort, baseline immunosuppression using mycophenolate was associated with severe COVID-19, especially at doses higher than one gram per day. This association was not seen with calcineurin inhibitors or everolimus. The authors propose this may be related to a synergistic effect of mycophenolate and COVID-19 depleting Tlymphocytes. 59, 60 Several studies since then have investigated immunosuppression in transplant recipients with COVID-19. One recent study from a large multi-center cohort of over 50 transplant centers investigated COVID-19 in 482 solid organ transplant recipients, of whom 73 patients were liver transplant recipients. Various measures of immunosuppression intensity did not show an association with mortality risk, however granular data on liver transplant recipients specifically was not investigated. 64 In the COLD consortium, including 112 liver transplant recipients from 15 medical centers in the US, immunosuppression was modified in 49.4% of patients, with more severe disease associated with a greater likelihood of change in immunosuppression. 33.3% of patients had mycophenolate held, with a decrease in tacrolimus or holding tacrolimus in 25.9% and 4.9% of patients, respectively. Only one patient had acute cellular rejection, and changes in immunosuppression were not associated with risk of acute liver injury or risk of mortality. 62 These rates of immunosuppression modification are similar to those seen in a European multicenter prospective study of 57 liver transplant recipients, with immunosuppression reduction seen in 37% and discontinuation in 7% of patients, with no impact on patient outcomes. 68 

This article is protected by copyright. All rights reserved There additionally appears to be prolonged viral shedding among solid organ transplant recipients.

One recent study included 60 solid organ transplant recipients with positive SARS-CoV-2 PCR admitted to the hospital; 21% of patients had a positive SARS-CoV-2 PCR detected at least 20 days after symptom onset and had a low cycle threshold, or high SARS-CoV-2 viral load, suggesting prolonged high viral burden among this patient population. 71

The safety and efficacy of the currently available SARS-CoV-2 vaccines are not yet established among liver transplant candidates and recipients. However given the high rates of morbidity and mortality in this population associated with infection, there have been broad recommendations in support of vaccination in this context. 72, 73 Both the American Society of Transplantation and American Association for the Study of Liver Diseases have released preliminary guidance on COVID-19 vaccination in liver transplant candidates and recipients. 73, 74 At this time, the recommendation is that transplant candidates and their household contacts receive the COVID-19 vaccine once available to them. The vaccine series should be completed at least two weeks prior to transplant, if possible. In transplant recipients, COVID-19 vaccination is also recommended, however with one consideration being that patients who may require B or T cell ablative therapies post-transplant wait until three months after transplantation to begin the vaccine series. Solid organ transplant recipients are known to have a lowered response to vaccination [75] [76] [77] ; therefore, prioritization of vaccination in the pre-transplant population may be especially important, and we expect this to be an important consideration as widespread vaccination for COVID-19 becomes readily available.

In early data among solid organ transplant recipients, it appears that they may have a lower antibody related response to natural infection. 78 In this study, factors associated with transplant and degree of immunosuppression (such as time from transplant and number of immunosuppressive agents) were predictive of antibody non-response. There is also concern about response to vaccination. In one of the first studies to describe immunogenicity of the first dose of the mRNA SARS-CoV-2 vaccine among 436 solid organ transplant recipients, only 17% of patients mounted a

This article is protected by copyright. All rights reserved detectable anti-spike antibody response at a median of 20 days after the first dose of the vaccine. 79 However, data on the antibody response after the full vaccination course, and perhaps more importantly on cellular immune responses and infection/re-infection in vaccinated patients will be highly anticipated. 

This article is protected by copyright. All rights reserved Accepted Article

An interactive web-based dashboard to track COVID-19 in real time

Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large US Cohort

Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States

Extrapulmonary manifestations of COVID-19

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the united states: A multicenter research network study

Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis

In-Person Outreach and Telemedicine in Liver and Intestinal Transplant: A Survey of National Practices, Impact of COVID-19 and Areas of Opportunity

Liver transplantation in the United States during the COVID-19 pandemic: national and center-level responses

Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability

Changes in liver allocation in United States

Clinical and Best Practice Advice for Hepatology and Liver Transplant Providers during the COVID-19 Pandemic: AASLD Expert Panel Conensus Statement

Summary of current evidence and information -donor SARS-CoV-2 testing and organ recovery from donors with a history of COVID-19

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical Features of COVID-19-Related Liver Functional Abnormality

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19

Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Clinical Characteristics of Covid-19 in

COVID-19 presenting as fulminant hepatic failure: A case report

Post-COVID-19 Cholangiopathy: A Novel Entity

Factors associated with COVID-19-related death using OpenSAFELY

Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury …

Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study

Outcome of COVID-19 in Patients with Autoimmune Hepatitis: an International Multi-Centre Study

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Hepatic disorders with the use of remdesivir for coronavirus 2019

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series

Remdesivir for the treatment of Covid-19-preliminary report

Center for Drug Evaluation and Research. Food and Drug Administration

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis

Integrated safety in tocilizumab clinical trials

Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19

2019-nCoV): Recommendations and Guidance for Organ Donor Testing

COVID-19 Information | American Society of Transplantation

Chronic Liver Disease and COVID-19: Alcohol Use Disorder/Alcohol-Associated Liver Disease, Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Autoimmune Liver Disease, and Compensated Cirrhosis

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Liver transplantation in a patient with human immunodeficiency virus and COVID-19

Liver transplantation in a patient after COVID-19 -Rapid loss of antibodies and prolonged viral RNA shedding

Successful liver transplantation in a patient recovered from COVID-19

Early liver transplantation after COVID-19 infection: The first report

Living Donor Hepatectomy After Proven SARS-CoV-2 Infection: First Report of 9 Cases From 3 Centers

Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

COVID-19 in solid organ transplant recipients: Initial report from the US epicenter

COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry

Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

Liver Injury in Liver Transplant Recipients with Coronavirus Disease 2019 (COVID-19): US Multicenter Experience

Clinical Characteristics, Hospitalization, and Mortality Rates of Coronavirus Disease 2019 Among Liver Transplant Patients in the United States

COVID-19 in solid organ transplant: A multicenter cohort study

Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study

Antivirals for COVID-19 in Solid Organ Transplant Recipients

COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation

COVID-19 in an international European liver transplant recipient cohort

Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study

SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients

Cycle Thresholds Among Solid Organ Transplant Recipients Testing Positive for SARS-CoV-2

AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 in Patients with Liver Disease

AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease

COVID-19 Vaccine FAQ Sheet. AST 2021

Vaccination of solid-organ transplantation candidates

Vaccination of the solid organ transplant recipient

Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice

Prevalence and Predictors of SARS-CoV-2 Antibodies among Solid Organ Transplant Recipients with Confirmed Infection

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)